

Cardiovascular and coronary risk estimation in hypertension management

Erica J Wallis, Lawrence E Ramsay, and Peter R Jackson

Web-only References

Staessen J, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, *et al* for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment of older patients with isolated systolic hypertension. *Lancet* 1997;**350**:757-764.

Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, Poulter NR, Russell G. Guidelines for the management hypertension: report of the third working party of the British Hypertension Society. *J Hypertens* 1999;**13**:569-592.

Ramsay LE, Haq IU, Yeo WW, Jackson PR. Interpretation of prospective trial in hypertension: do treatment guidelines accurately reflect current evidence? *J Hypertens* 1996;**14**(suppl 5):S187-S194.

Ramsay LE, Wallis EJ, Yeo WW, Jackson PR. The rationale for differing national recommendations for the treatment of hypertension. *Am J Hypertens* 1998;**11**:79S-88S.

Egger M, Davey Smith G. Risks and benefits of treating mild hypertension: a misleading meta-analysis? *J Hypertens* 1995;**13**:813-815.

Neaton JD, Grimm RH, Prineas RJ, Stamler J, Granditis GA, Elmer PJ *et al* for the Treatment of Mild Hypertension Study Group. Treatment of Mild Hypertension Study. Final results. *JAMA* 1993;**270**:713-724.

Alderman MH, Lamport B. Labelling of hypertensives: a review of the data. *Clin Epidemiol* 1990;**43**:195-200.

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000;**342**:145-153.

PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. *Lancet* 2001;**358**:1033-1041.

Hingorani AD, Vallance P. A simple computer program for guiding management of cardiovascular risk factors and prescribing. *BMJ* 1999;**318**:101-105.

Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension guidelines for the management of hypertension. *J Hypertens* 1999;**17**:151-183.

Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. *Arch Intern Med* 1997;**157**:2413-2446.

Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for Northern European populations? A comparison of methods for estimating absolute coronary risk in high-risk men. *Heart* 1998;**81**:40-46.

Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. *Eur Heart J* 2000;**21**:365-370.

Anand SS, Yusuf S, Vuksen V et. al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). *Lancet* 2000;**356**:279-84.

Haq IU, Wallis EJ, Yeo WW, Jackson PR, Ramsay LE. The impact of ambulatory blood pressure on estimation of cardiovascular risk in mild hypertension. British Hypertension Society, Bristol. *J Hypertens* 1997;**15**:1540-1541.

Johannesson M. Cost-effectiveness of hypertension treatment in Sweden. *Pharmacoeconomics* 1995;**7**:242-250.

Nicholson K, Ramsay LE, Haq IU, Wallis EJ, Ghahramani P, Jackson PR, Yeo WW. Factors affecting patients' acceptance of drug therapy to prevent myocardial infarction. *Br J Clin Pharmacol* 1999;**47**:575P.

Leaman H, Jackson PR. What benefit do patients expect from adding second and third antihypertensive drugs? *Br J Clin Pharmacol* 2002;**53**:93-99.

Williams A. Rationing health care by age. The case for. *BMJ* 1997;**314**:820-822.

McNeil BJ, Pauker SG, Sox HC, Tversky A. On the elicitation of preferences for alternative therapies. *N Engl J Med* 1982;**306**:1259-1262.